Clinical study of lamivudine combined adefovir dipivoxil treatment for decompensated liver cirrhosis due to chronic hepatitis B.

Objective To investigate the clinical efficacy of lamivudine and adefovir dipivoxil therapy in patients with decompensated liver cirrhosis resulting from hepatitis B.Methods 68 patients with decompensated liver cirrhosis resulting from hepatitis B were included and 22 patients with lamivudine 100 mg and adefovir 10 mg once daily,23 with lamivudine 100 mg once daily and 23 with adefovir dipivoxil 10 mg once daily for more than six months.Results The negative-transformed rate of HBV DNA in combined group,lamivudine group and adefovir dipivoxil group were 81.8%,47.8% and 43.5%,respectively;and the Child-Pugh scores were (6.8±1.4) scores,(7.2±1.5) scores and (7.4±1.9) scores,respectively.Conclusion Combination of lamivudine and adefovir dipivoxil in treatment of decompensated liver cirrhosis resulting from hepatitis B has an advantage over lamivudine or adefovir dipivoxil treatment alone.Lamivudine combined with adefovir dipivoxil treatment of hepatitis B cirrhosis shows no resistance and patients could receive a long-term drugs with stable condition.